As artificial intelligence (AI) gets more deeply embedded into the drug discovery systems of global pharma majors, an increasing number of use cases continue to emerge, some with the potential to shake the very foundations of how things have traditionally been done and others with more peripheral applications.
Late last week, VantAI - Roivant Sciences’s AI-enabled drug discovery unit - launched Neo-1, an AI model to unify de...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?